Farrell James J, van Rijnsoever Marius, Elsaleh Hany
Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Cancer Biomark. 2005;1(2-3):157-75. doi: 10.3233/cbm-2005-12-304.
The role of early detection in cancer has shown improved survival for certain cancers, including colon cancer, cervical cancer and breast cancer. The possibility for early detection of pancreatic cancer may be realized by an improved understanding of the histology and molecular genetics of precursor lesions and cancerous lesions in pancreatic cancer and the development of sensitive and specific screening tests (both invasive and non-invasive) to detect early pancreatic cancer. The NIH-NCI Early Detection Research Network (EDRN) in Pancreatic Cancer has been focussed on the development and validation of new biomarkers for the detection of early pancreatic cancer. This review will focus on our understanding of the histologic and molecular model of pancreatic carcinogenesis, current strategies and limitations of screening for pancreatic cancer and the development and validation of new biomarkers for the early detection of pancreatic cancer.
早期检测在癌症治疗中已显示出能提高某些癌症（包括结肠癌、宫颈癌和乳腺癌）的生存率。通过加深对胰腺癌前体病变和癌性病变的组织学及分子遗传学的理解，以及开发灵敏且特异的筛查测试（包括侵入性和非侵入性测试）以检测早期胰腺癌，实现早期检测胰腺癌是有可能的。美国国立卫生研究院-国立癌症研究所胰腺癌早期检测研究网络（EDRN）一直专注于开发和验证用于检测早期胰腺癌的新生物标志物。本综述将聚焦于我们对胰腺癌发生的组织学和分子模型的理解、当前胰腺癌筛查的策略及局限性，以及用于早期检测胰腺癌的新生物标志物的开发和验证。
